MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1371/journal.pntd.0002727

Медицинская библиотека · PLoS neglected tropical diseases · 2014

Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis.

Houghton Raymond L, Reed Dana E, Hubbard Mark A, Dillon Michael J, Chen Hongjing, Currie Bart J, Mayo Mark, Sarovich Derek S, Theobald Vanessa, Limmathurotsakul Direk, Wongsuvan Gumphol, Chantratita Narisara, Peacock Sharon J, Hoffmaster Alex R, Duval Brea, Brett Paul J, Burtnick Mary N, Aucoin David P

Оценочное исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Burkholderia pseudomallei is a soil-dwelling bacterium and the causative agent of melioidosis. Isolation of B. pseudomallei from clinical samples is the "gold standard" for the diagnosis of melioidosis; results can take 3-7 days to produce. Alternatively, antibody-based tests have low specificity due to a high percentage of seropositive individuals in endemic areas. There is a clear need to develop a rapid point-of-care antigen detection assay for the diagnosis of melioidosis. Previously, we employed In vivo Microbial Antigen Discovery (InMAD) to identify potential B. pseudomallei diagnostic biomarkers. The B. pseudomallei capsular polysaccharide (CPS) and numerous protein antigens were identified as potential candidates. Here, we describe the development of a diagnostic immunoassay based on the detection of CPS. Following production of a CPS-specific monoclonal antibody (mAb), an antigen-capture immunoassay was developed to determine the concentration of CPS within a panel of melioidosis patient serum and urine samples. The same mAb was used to produce a prototype Active Melioidosis Detect Lateral Flow Immunoassay (AMD LFI); the limit of detection of the LFI for CPS is comparable to the antigen-capture immunoassay (∼0.2 ng/ml). The analytical reactivity (inclusivity) of the AMD LFI was 98.7% (76/77) when tested against a large panel of B. pseudomallei isolates. Analytical specificity (cross-reactivity) testing determined that 97.2% of B. pseudomallei near neighbor species (35/36) were not reactive. The non-reactive B. pseudomallei strain and the reactive near neighbor strain can be explained through genetic sequence analysis. Importantly, we show the AMD LFI is capable of detecting CPS in a variety of patient samples. The LFI is currently being evaluated in Thailand and Australia; the focus is to optimize and validate testing procedures on melioidosis patient samples prior to initiation of a large, multisite pre-clinical evaluation.

Для цитирования: Houghton Raymond L, Reed Dana E, Hubbard Mark A, Dillon Michael J, Chen Hongjing, Currie Bart J, Mayo Mark, Sarovich Derek S, Theobald Vanessa, Limmathurotsakul Direk, Wongsuvan Gumphol, Chantratita Narisara, Peacock Sharon J, Hoffmaster Alex R, Duval Brea, Brett Paul J, Burtnick Mary N, Aucoin David P. Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis.. PLoS neglected tropical diseases. 2014. DOI: 10.1371/journal.pntd.0002727.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.